Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.8K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.8K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

2.1K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.1K
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

2.0K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
2.0K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

2.1K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
2.1K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

On the Importance of Including Cohesive Zone Models in Modelling Mixed-Mode Aneurysm Rupture.

Cardiovascular engineering and technology·2024
Same author

NOVEL ANALYTICAL STUDY FOR REACTION INTERMEDIATES IN THE PRIMARY RADIATION INTERACTION OF DNA USING A SYNCHROTRON RADIATION-INDUCED LUMINESCENCE SPECTROSCOPY.

Radiation protection dosimetry·2019
Same author

Outcome and clinical course of EHEC O104 infection in hospitalized patients: A prospective single center study.

PloS one·2018
Same author

The prevalence of depression in the North West Adelaide Health Study.

Acta neuropsychiatrica·2016
Same author

Depression and health risk factors in the North West Adelaide Health Study.

Acta neuropsychiatrica·2016
Same author

Letter to the Editor.

American journal of audiology·2015

Related Experiment Video

Updated: May 3, 2026

Videomorphometric Analysis of Hypoxic Pulmonary Vasoconstriction of Intra-pulmonary Arteries Using Murine Precision Cut Lung Slices
13:32

Videomorphometric Analysis of Hypoxic Pulmonary Vasoconstriction of Intra-pulmonary Arteries Using Murine Precision Cut Lung Slices

Published on: January 14, 2014

12.6K

Inhaled verapamil in histamine-induced bronchoconstriction.

E McIntyre, B Fitzgibbon, H Otto

    The Journal of Allergy and Clinical Immunology
    |April 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Inhaled verapamil did not significantly protect against histamine-induced bronchoconstriction in asthma patients. Salbutamol provided significant protection, while verapamil showed limited effects in some cases.

    More Related Videos

    Humanized Mediator Release Assay as a Read-Out for Allergen Potency
    10:22

    Humanized Mediator Release Assay as a Read-Out for Allergen Potency

    Published on: June 29, 2021

    4.9K
    Isolation of Intrapulmonary Artery and Smooth Muscle Cells to Investigate Vascular Responses
    07:56

    Isolation of Intrapulmonary Artery and Smooth Muscle Cells to Investigate Vascular Responses

    Published on: June 8, 2022

    4.3K

    Related Experiment Videos

    Last Updated: May 3, 2026

    Videomorphometric Analysis of Hypoxic Pulmonary Vasoconstriction of Intra-pulmonary Arteries Using Murine Precision Cut Lung Slices
    13:32

    Videomorphometric Analysis of Hypoxic Pulmonary Vasoconstriction of Intra-pulmonary Arteries Using Murine Precision Cut Lung Slices

    Published on: January 14, 2014

    12.6K
    Humanized Mediator Release Assay as a Read-Out for Allergen Potency
    10:22

    Humanized Mediator Release Assay as a Read-Out for Allergen Potency

    Published on: June 29, 2021

    4.9K
    Isolation of Intrapulmonary Artery and Smooth Muscle Cells to Investigate Vascular Responses
    07:56

    Isolation of Intrapulmonary Artery and Smooth Muscle Cells to Investigate Vascular Responses

    Published on: June 8, 2022

    4.3K

    Area of Science:

    • Pulmonology
    • Pharmacology

    Background:

    • Asthma is a chronic respiratory disease characterized by airway inflammation and hyperresponsiveness.
    • Histamine is a potent bronchoconstrictor that can trigger asthma symptoms.

    Purpose of the Study:

    • To evaluate the protective effects of inhaled verapamil against histamine-induced bronchoconstriction in asthmatic subjects.
    • To compare verapamil's efficacy with salbutamol and a saline control.

    Main Methods:

    • A double-blind, placebo-controlled trial involving fifteen asthmatic subjects.
    • Administration of inhaled verapamil, salbutamol, or saline prior to histamine challenges.
    • Assessment of histamine-induced bronchoconstriction through spirometry.

    Main Results:

    • Inhaled verapamil did not provide significant protection against bronchoconstriction when administered between repeated histamine challenges.
    • Salbutamol demonstrated significant protection (p < 0.001) against histamine-induced bronchoconstriction.
    • Limited but significant protection (p < 0.05) was observed with verapamil before a single histamine challenge in a subset of eight subjects.

    Conclusions:

    • Inhaled verapamil appears to have minimal protective effects against histamine-induced bronchoconstriction in asthma.
    • The variability in verapamil's effect may be due to inter-subject differences or a blocking effect from prior histamine exposure.